Quercetin Human Clinical Trials: What the RCT Evidence Shows

Expert Summary

Quercetin has the most extensive human clinical trial database of any flavonoid senolytic. Consistent findings include: blood pressure reduction (confirmed in 7 RCTs), CRP reduction (confirmed in 4 meta-analyses), LDL oxidation reduction (consistent across 5 trials), and — in the D+Q senolytic context — measurable reduction of senescent cell biomarkers (PMID: 29988130).

Key Facts

As an Amazon Associate, Stacking Years earns from qualifying purchases.

Thorne Quercetin Phytosome

250 mg quercetin phytosome per capsule

Quercetin phytosome capsules.

Best for: comparing a quercetin phytosome option in Key Facts

View on Amazon · Affiliate link

Frequently Asked Questions

Why do some quercetin RCTs show no effect?

Studies using low-dose (< 200 mg/day) standard quercetin aglycone often find no significant effects — consistent with the poor bioavailability of this form. Studies using ≥500 mg/day or phytosome forms consistently show benefits.

What is the best-quality quercetin RCT?

The Xu et al. (Nature Medicine 2018) D+Q trial is considered the highest-impact quercetin clinical study for aging. For cardiovascular evidence, the Larson et al. (2012) crossover RCT in arterial stiffness is a landmark reference.

Are quercetin studies funded by supplement companies?

Some are. Industry funding does not automatically invalidate data but warrants scrutiny. The D+Q trials are funded by NIH and the National Institute on Aging — government funding with no commercial bias.

Get the free Longevity Supplement Starter Guide

Sign up for the guide and occasional Stacking Years updates. The guide is available on the confirmation screen.

Scientific References